RxDoctor Payments Data

Christopher Estopinal, MD

Ophthalmology · Richmond, VANPI 1760778401

Payments from drug & device makers

$1,296in general payments, 2019–2025

Across 48 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$248
  • Glaukos Corporation$234
  • Omeros Corporation$163
  • Ocular Therapeutix, Inc.$142
  • Sun Pharmaceutical Industries Inc.$123
  • Oyster Point Pharma, Inc.$57
  • plus $330 from 14 others

What the payments were for

  • Food & beverage$1,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,296 in reported general payments places this provider in the 55th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$559,807
Medicare patients
1,439
Services billed
4,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine78$86,913
XiidraLifitegrast29$47,525
TyrvayaVarenicline Tartrate34$28,342
CequaCyclosporine27$28,265
Prednisolone Acetate415$18,278
LumiganBimatoprost31$14,957
Cyclosporine26$13,933
MoxifloxacinMoxifloxacin Hcl258$6,401
ValacyclovirValacyclovir Hcl126$4,264
Latanoprost339$4,056
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$3,910
LotemaxLoteprednol Etabonate12$3,627
Travoprost16$3,335
Loteprednol Etabonate26$2,907
Timolol Maleate163$2,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$29$101,869109 claims
Oyster Point Pharma, Inc.Tyrvaya$57$28,34234 claims
Sun Pharmaceutical Industries Inc.Cequa$123$28,26527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →